As previously announced, the 1-for-33 reverse stock split will automatically convert thirty-three current shares of TransCode’s common stock into one new share of common stock. No fractional shares ...

TransCode Therapeutics ( (RNAZ) ) has provided an update.

Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's ...

TransCode Therapeutics, Inc. BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC ...

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to ...

(RTTNews) - TransCode Therapeutics, Inc. (RNAZ), a company focused on cancer treatment using RNA therapeutics, said on Monday that its Board has approved a 1-for-33 reverse stock split. This move ...

About TransCode Therapeutics TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design ...

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in TransCode Therapeutics Inc (NASDAQ:RNAZ) decreased during the last reporting period, falling from 1.22M to 743.58K. This put 4.31% of the company's publicly available shares short.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead ...